佩索利单抗(Spesolimab) - 药物靶点：IL-36R_在研适应症：脓疱型银屑病，泛发性脓疱型银屑病，坏疽性脓皮病_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Immunoglobulin G1, anti-(human interleukin 36 receptor) (humanized monoclonal BI 655130 gamma1-chain), disulfide with humanized monoclonal BI 655130 kappa-chain, dimer、Spesolimab (genetical recombination) (JAN)、Spesolimab (INN)

+ [9]

靶点

IL-36R

作用方式

抑制剂

作用机制

IL-36R抑制剂(白细胞介素-36受体蛋白抑制剂)

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病其他疾病+ [2]

在研适应症

脓疱型银屑病泛发性脓疱型银屑病坏疽性脓皮病+ [2]

非在研适应症

溃疡性结肠炎克罗恩病肠梗阻+ [4]

原研机构

Boehringer Ingelheim International GmbH

在研机构

Boehringer Ingelheim GmbHBoehringer Ingelheim International GmbHBoehringer Ingelheim Pharma GmbH & Co., KG

+ [6]

非在研机构-

权益机构

Boehringer Ingelheim GmbH

LEO Pharma A/S

最高研发阶段批准上市

首次获批日期

美国 (2022-09-01),

泛发性脓疱型银屑病

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、孤儿药 (美国)、优先审评 (中国)、突破性疗法 (中国)、孤儿药 (韩国)、孤儿药 (瑞士)、突破性疗法 (中国台湾)、优先审评 (美国)、孤儿药 (澳大利亚)

登录后查看时间轴

结构/序列

Sequence Code 176702L

来源: *****

Sequence Code 9071670H

来源: *****

关联

42

项与佩索利单抗相关的临床试验

NCT06886009

/ Not yet recruitingN/A

A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Spesolimab in Korean Patients With Flares With Generalized Pustular Psoriasis

The primary and secondary objectives are to respectively monitor the safety and effectiveness of Spesolimab IV in Korean patients with flares with generalized pustular psoriasis (GPP) in a routine medical practice.

开始日期2025-08-29

申办/合作机构

Boehringer Ingelheim GmbH

CTR20244695

/ Recruiting临床3期

一项在需要全身治疗的成人溃疡型坏疽性脓皮病（PG）患者中评价佩索利单抗（BI 655130）的安全性和有效性的多中心、随机、安慰剂对照、双盲、平行组试验

本试验拟在溃疡型PG试验受试者中评价佩索利单抗重复给药相比安慰剂（两种药物均联合口服皮质类固醇：天泼尼松或泼尼松龙）的安全性、有效性、PK和免疫原性。主要目的是证明在第26周前任何时间目标PG溃疡达到完全闭合（PG面积减少100%，PGAR-100）的试验受试者比例差异方面，佩索利单抗优效于安慰剂。次要目的是证明佩索利单抗在（关键）次要终点方面优效于安慰剂。

开始日期2025-02-20

申办/合作机构

勃林格殷格翰（中国）投资有限公司

[+2]

NCT06624670

/ Recruiting临床3期

A Multi-centre, Randomised, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) in Adult Patients With Ulcerative Pyoderma Gangrenosum (PG) Who Require Systemic Therapy

The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers. This study is open to adults with ulcerative PG with at least 1 ulcer that measures between 5 cm^2 to 80 cm^2 in size.
This study has 2 parts. In Part 1, participants are put into groups randomly, which means by chance. 1 group gets spesolimab and the other group gets placebo. Placebo injections look like spesolimab injections, but do not contain any medicine. Every participant has a 2 in 3 chance of getting spesolimab. For the first 8 weeks, participants also take corticosteroid medicine by mouth.
In Part 2, participants are put into groups again. Participants without open ulcers have an equal chance of getting spesolimab or placebo. Participants with open skin ulcers will get spesolimab.
In both parts, participants receive spesolimab or placebo as an infusion into a vein every 4 weeks.
Participants are in the study for about 1.5 years. During this time, they visit the study site 20 times. At study visits, doctors check the participant's skin for signs of PG. The doctors also regularly check participants' health and take note of any unwanted effects. The results of the groups are compared to see whether the treatment works.

开始日期2025-02-04

申办/合作机构

Boehringer Ingelheim GmbH

100 项与佩索利单抗相关的临床结果

登录后查看更多信息

100 项与佩索利单抗相关的转化医学

登录后查看更多信息

100 项与佩索利单抗相关的专利（医药）

登录后查看更多信息

151

项与佩索利单抗相关的文献（医药）

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Successful treatment of generalized pustular psoriasis during pregnancy with secukinumab in a patient hypersensitive to spesolimab: a case report

Article

作者: Zhang, Yun ; Peng, Guoyao ; Yu, Tao ; Zhang, Hongwei ; Nie, Xinyi ; Liao, Chengcheng ; Li, Xia ; Xiang, Jie ; Luo, Jiaxin ; Luo, Liping ; Li, You ; Zhang, Shuang

OBJECTIVE:

Generalized pustular psoriasis (GPP) is a rare autoinflammatory skin disease characterized by recurrent, widespread eruption of sterile pustules rich in neutrophils. In addition to skin manifestations, this condition may be accompanied by fever, muscle pain, joint pain, systemic inflammation, or organ failure. GPP during pregnancy poses a serious threat to both mother and fetus, with limited options for medication. This study aimed to evaluate the safety of secukinumab during pregnancy as a treatment option for psoriasis.

MATERIALS AND METHODS:

We report the case of a 35-year-old pregnant woman presenting with extensive, confluent erythematous scaly plaques and numerous pustules, accompanied by fever. Over the past few years, her lesions showed remission following treatment with corticosteroids, traditional Chinese medicine, and secukinumab. However, after a brief remission with spesolimab, the lesions recurred and no significant improvement was obtained with glucocorticoid therapy. Secukinumab treatment was then initiated.

RESULTS:

Secukinumab was administered subcutaneously at a dose of 300 mg at weeks 0, 1, 2, 3, 4, and 8. Following treatment, GPP symptoms were reduced, and fetal development remained normal. A healthy boy was delivered vaginally at term.

CONCLUSION:

Our findings provide evidence that secukinumab is an effective and safe treatment option for GPP during pregnancy.

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Expanding the therapeutic horizons of spesolimab: a review of off-label applications for inflammatory skin diseases

Review

作者: Zhang, Hanlin ; Tang, Keyun ; Zhang, Xinyi ; Jin, Hongzhong ; Zhou, Jia

PURPOSE:

This review aims to outline the crucial role of IL-36 signaling in inflammatory skin diseases and summarize the therapeutic potential of spesolimab. Our goal is to provide insights into the off-label applications of spesolimab and future directions for its use in treating other challenging skin diseases.

MATERIALS AND METHODS:

We conducted a comprehensive literature search across PubMed, Embase, Web of Science, MEDLINE, Scopus, and the Cochrane Library to identify relevant studies. For RCTs, we additionally searched the ClinicalTrials.gov database.

RESULTS:

In this review, we examine its off-label applications for conditions such as palmoplantar pustulosis, acrodermatitis continua of Hallopeau, hidradenitis suppurativa, pyoderma gangrenosum, and acute generalized exanthematous pustulosis. This review also explores the role of IL-36 in the pathophysiology of these disorders and discusses how spesolimab may address the limitations of current therapies for refractory cases. Randomized controlled trials and case reports are summarized to highlight the efficacy and tolerability of spesolimab across various inflammatory skin conditions. We highlight the challenges presented by the absence of standardized treatment guidelines and the need for larger clinical trials.

CONCLUSIONS:

This review underscores the potential of spesolimab to enhance treatment strategies for inflammatory skin diseases.

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Successful treatment of etanercept- and adalimumab-resistant pyoderma gangrenosum with spesolimab, moderate-dose corticosteroids, and minocycline

Article

作者: Zhang, Hanlin ; Wu, Chao ; Jin, Hongzhong

PURPOSE:

Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis characterized by rapidly developing, painful ulcers. This study explores the potential of spesolimab, an anti-IL-36R antibody, as a therapeutic option for refractory PG.

MATERIALS AND METHODS:

We report a case of a 48-year-old male with refractory PG who failed to respond to etanercept and adalimumab. Upon admission, the patient presented with extensive, painful ulcerations on the trunk and extremities. He was started on oral methylprednisolone (32 mg/day) and minocycline (50 mg twice daily). After a week, minimal improvement was observed. After reviewing the screening results and discussing treatment options, the patient received two doses of spesolimab (900 mg intravenously) administered two weeks apart.

RESULTS:

Marked clinical improvement was observed after spesolimab initiation. Complete ulcer healing was achieved within six weeks of starting spesolimab, with no adverse effects reported.

CONCLUSIONS:

This case demonstrates the potential efficacy of spesolimab for treating refractory PG, particularly in patients unresponsive to TNF-α inhibitors. Despite the added complexity of the patient's underlying HBV infection and elevated M-protein, no HBV reactivation or other hematologic complications occurred. Further studies are needed to validate its role in managing PG and other neutrophilic dermatoses.

199

项与佩索利单抗相关的新闻（医药）

2025-07-29

·Pharmaceutical Technology

Re-Vana Therapeutics and Boehringer Ingelheim collaborate for eye therapies

The partnership focuses on developing extended-release therapies for various eye diseases. Credit: Orawan Pattarawimonchai / Shutterstock.com. Re-Vana Therapeutics, a spin-out from Queen’s University, has entered a partnership and licence agreement with Boehringer Ingelheim for the development of ophthalmic therapies. The partnership focuses on developing extended-release therapies for various eye diseases. Boehringer Ingelheim has a diverse pipeline in eye care, which features four assets currently in Phase II development. Treating ophthalmic diseases frequently necessitates regular injections directly into the eye, a process that can be quite burdensome for patients. To address this challenge, Re-Vana’s drug delivery technology, initially developed at Queen’s, is designed to release treatments gradually over six to 12 months. This approach will reduce the frequency of injections required for conditions such as macular degeneration. As part of the collaboration, Boehringer Ingelheim will undertake up to three projects annually across various therapeutic modalities. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The two companies will work together to manage Re-Vana’s feasibility along with development efforts for the extended-release programmes. However, Boehringer Ingelheim will take full responsibility for the products’ development, approval from regulatory authorities, and worldwide commercialisation. Boehringer Ingelheim’s mental health, eye health and emerging areas global head Nedim Pipic said: “We’re looking forward to teaming up with Re-Vana to push the boundaries of what’s possible in eye health. “Together, we want to tackle the limits of today’s treatments – aiming to help people keep their sight, with fewer injections. This partnership is a bold step forward in our mission to protect vision and ease the burden on patients.” The agreement grants Boehringer Ingelheim exclusive rights to target development and includes both upfront and milestone payments tied to development, regulatory approval, and commercial success for Re-Vana. The total potential value of the deal exceeds $1bn for the first three targets, besides royalty payments based on net sales. During this month, LEO Pharma acquired the rights to Boehringer Ingelheim’s psoriasis drug, Spevigo (spesolimab), for €90m ($105m). Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

引进/卖出并购临床2期

2025-07-24

·创鉴汇

中国生物制药约5亿美元收购礼新医药；抗体与小分子交易持续领跑 | 一周交易

据创鉴汇不完全统计，7月14日至7月20日全球生物制药领域共披露19起交易事件，潜在交易总额近7亿美元。上周超亿美元的交易集中于抗体及小分子药物，涉及癌症、中枢神经及眼科疾病等领域，反映了行业对这些高需求方向的持续投入。JCR公司与Acumen公司达成了一项潜在总额5.55亿美元的合作，共同开发阿尔茨海默病（AD）创新疗法。双方旨在利用JCR的血脑屏障穿透技术平台，将Acumen开发的选择性抗体递送至脑内，靶向清除AD发病和进展的关键病理驱动因素——毒性可溶性淀粉样β寡聚体（AβO）。此次合作有望克服血脑屏障这一关键障碍，从而改善治疗效果。癌症领域，正大天晴母公司中国生物制药于7月15日宣布，以约5亿美元收购礼新医药，礼新医药将成为其全资子公司。礼新医药拥有多个双抗和抗体偶联药物（ADC）技术平台，管线覆盖肺癌、消化道癌症、自免疾病等。目前核心产品PD-1/VEGF双抗LM-299、ADC药物LM-305和LM-302、单抗LM-108等8项资产处于临床阶段。通过此次收购，中国生物制药将加速该领域的战略布局，增强创新分子的研发能力。同一天，Repare Therapeutics以潜在总额2.67亿美元将PKMYT1抑制剂lunresertib的全球开发与商业化权利授权给瑞士Debiopharm。据悉，该药物在难治性实体瘤的早期临床试验中表现出积极效果。眼科疾病领域，法国Nicox授权兴和株式会社（Kowa）开发和商业化NCX 470，用于治疗青光眼和眼压过高。协议价值最高可达1.99亿欧元。皮肤疾病领域，勃林格殷格翰将SPEVIGO（spesolimab）的商业化及后续开发权授予LEO Pharma。SPEVIGO是一种单克隆抗体，可靶向并阻断白细胞介素36（IL-36）受体的激活，用于治疗泛发性脓疱性银屑病（GPP），目前已在全球40多个国家和地区上市。交易总金额包括9000万欧元的预付款，以及里程碑付款和分级版税，预计将于2025年下半年完成。读者们请星标⭐创鉴汇，第一时间收到推送免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转发/复制至其他平台。转发授权请在「创鉴汇」微信公众号留言联系我们。更多数据内容推荐点击“在看”，分享创鉴汇健康新动态

2025-07-21

·PMLiVE

LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront

LEO Pharma and Boehringer Ingelheim have entered into a partnership to commercialise and advance the development of Boehringer’s generalised pustular psoriasis (GPP) drug Spevigo (spesolimab). The exclusive global licensing and transfer agreement, which is expected to close later this year, will see dermatology specialist LEO take on responsibility for the commercialisation and further development of Spevigo, using its global commercial platform to raise disease awareness and secure access for GPP patients. In exchange, Boehringer is set to receive €90m upfront, alongside undisclosed milestone payments and tiered royalties. GPP is a rare and unpredictable skin condition characterised by recurrent flares of pustules covering large areas of the body. These flares can be life-threatening due to the potential for serious complications such as sepsis, heart and kidney failure, and many GPP patients also live with various co-morbidities. Spevigo is a selective antibody that blocks the activation of the interleukin-36 (IL-36) receptor, a signalling pathway within the immune system shown to be involved in the pathogenesis of several auto-inflammatory diseases. It is the first approved treatment for GPP flares that specifically targets the IL-36 pathway and is currently available in more than 40 countries. LEO’s chief executive officer, Christophe Bourdon, said: “Partnering to bring Spevigo to more patients is more than a strategic step – it means the opportunity to help people living with GPP by addressing a disease with limited treatment options and aiming to improve their quality of life. “… Together, we have a powerful opportunity to expand access to innovative care and deliver meaningful progress for patients who have long been underserved.” The alliance extends beyond GPP, with an opportunity to evaluate the drug in additional skin conditions in which IL-36 is implicated. Shashank Deshpande, chairman of the board of managing directors and head of human pharma at Boehringer Ingelheim, said: “Spevigo holds a significant promise, and ensuring it reaches its full potential requires continued focus, and expertise in medical dermatology. “With over six decades of singular dedication to this field, LEO Pharma is exceptionally well-positioned to build on the strong foundation we’ve laid.”

上市批准引进/卖出

100 项与佩索利单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12066	-	-	DB15626

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
脓疱型银屑病	日本	Nippon Boehringer Ingelheim Co., Ltd.	2022-09-26
泛发性脓疱型银屑病	美国	Boehringer Ingelheim Pharmaceuticals, Inc.	2022-09-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
坏疽性脓皮病	临床3期	美国	Boehringer Ingelheim International GmbH	2025-02-04
坏疽性脓皮病	临床3期	美国	Boehringer Ingelheim GmbH	2025-02-04
坏疽性脓皮病	临床3期	中国	Boehringer Ingelheim GmbH	2025-02-04
坏疽性脓皮病	临床3期	日本	Boehringer Ingelheim GmbH	2025-02-04
坏疽性脓皮病	临床3期	日本	Boehringer Ingelheim International GmbH	2025-02-04
坏疽性脓皮病	临床3期	阿根廷	Boehringer Ingelheim International GmbH	2025-02-04
坏疽性脓皮病	临床3期	阿根廷	Boehringer Ingelheim GmbH	2025-02-04
坏疽性脓皮病	临床3期	澳大利亚	Boehringer Ingelheim GmbH	2025-02-04
坏疽性脓皮病	临床3期	澳大利亚	Boehringer Ingelheim International GmbH	2025-02-04
坏疽性脓皮病	临床3期	奥地利	Boehringer Ingelheim International GmbH	2025-02-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04876391 (CTgov)	临床2期	化脓性汗腺炎	45	Placebo matching 600 mg Spesolimab+Spesolimab 1200 mg (Prior Placebo (PP))	鏇餘糧築範積積齋糧糧 = 艱憲齋壓衊鬱衊醖醖糧夢窪餘獵夢鏇願積網襯 (鏇廠構膚積選製繭憲醖, 廠膚願鑰壓醖廠憲壓齋 ~ 鹽襯選簾願艱淵觸顧願) 更多	-	2025-06-08
				Placebo matching 1200 mg Spesolimab+Spesolimab 600 mg (Prior Spesolimab (PS))	鏇餘糧築範積積齋糧糧 = 繭製繭窪窪鏇製積艱夢夢窪餘獵夢鏇願積網襯 (鏇廠構膚積選製繭憲醖, 鑰願壓積衊壓構築衊鹹 ~ 積製範遞鹽糧鏇獵壓壓) 更多
NCT04362254 (CTgov)	临床2期	克罗恩病	12	Spesolimab	製積網獵夢願窪繭範選 = 顧膚築淵蓋積鹽構衊繭襯憲襯簾衊遞遞選鏇憲 (簾衊鹽壓憲願構憲積鏇, 艱窪範範壓範蓋簾廠艱 ~ 蓋簾繭積鹽夢憲網醖廠) 更多	-	2024-11-05
NCT04762277 (CTgov)	临床2期	化脓性汗腺炎	52	Placebo matching spesolimab - solution for infusion (Placebo)	艱糧製製鑰襯廠願醖艱(願網觸糧鑰廠鹽簾繭觸) = 窪壓糧願獵鏇獵衊觸獵鹽鏇顧製鏇壓夢遞鹹餘 (膚鑰醖憲選繭膚構醖選, 11.1) 更多	-	2024-10-09
				Spesolimab - solution for infusion (Spesolimab)	艱糧製製鑰襯廠願醖艱(願網觸糧鑰廠鹽簾繭觸) = 鏇壓積網簾製餘範窪餘鹽鏇顧製鏇壓夢遞鹹餘 (膚鑰醖憲選繭膚構醖選, 7.5) 更多
NCT05239039 (CTgov)	临床3期	泛发性脓疱型银屑病	39	spesolimab (Spesolimab Single Dose Treatment)	鏇鏇築簾膚積衊窪齋獵 = 鹹選觸夢鏇憲齋選鑰壓願壓壓艱膚憲積齋醖構 (衊鑰鑰積艱獵觸積餘網, 鏇餘繭積膚鬱繭簾顧遞 ~ 獵蓋選顧艱觸鏇淵範齋) 更多	-	2024-10-09
				spesolimab (Spesolimab Double Dose Treatment)	鏇鏇築簾膚積衊窪齋獵 = 構鑰夢艱觸窪廠鏇鬱網願壓壓艱膚憲積齋醖構 (衊鑰鑰積艱獵觸積餘網, 範繭顧淵憲顧顧觸築顧 ~ 鏇鬱觸糧遞衊選遞築獵) 更多
NCT05200247 (CTgov)	临床3期	泛发性脓疱型银屑病	11	Spesolimab	衊鹹鹹獵襯襯構顧顧廠 = 願製壓製襯鑰繭網鹽壓鬱顧鏇糧繭鬱顧簾觸觸 (膚鹽顧夢顧壓範衊觸鑰, 顧糧窪願獵鹽醖蓋襯簾 ~ 餘膚製願簾構顧鹽壓醖) 更多	-	2024-08-15
NCT03648541 (CTgov)	临床2期	溃疡性结肠炎	79	Spesolimab (300 mg Spesolimab s.c. Maintenance Treatment [q4w] for 336 Weeks)	醖鑰鑰膚願繭糧範範鬱 = 襯鹹築鑰積範蓋膚範齋鑰衊襯構淵廠構膚鹹獵 (膚廠選觸遞範顧簾襯窪, 獵鏇製網醖夢憲鑰窪範 ~ 積鹽醖繭積鏇齋鬱願餘) 更多	-	2024-07-03
				Spesolimab (1200 mg Spesolimab i.v. Re-induction Treatment [q4w] for 12 Weeks)	遞顧鑰餘積鹽獵糧製顧(築夢淵艱憲範夢築壓衊) = 繭觸襯鏇簾糧鏇糧淵膚鑰鬱夢網衊範襯選網遞 (願築壓壓艱願廠顧憲鏇, 鹽廠製廠範鏇餘襯窪醖 ~ 窪蓋夢憲願餘鏇齋淵醖) 更多
NCT04493424 (CTgov)	临床2期	手掌和足底脓疱病 \| 脓疱型银屑病	108	Spesolimab	艱衊醖齋積鏇艱淵築鑰 = 鹽築艱製壓窪夢觸淵膚築簾積齋觸選憲糧淵夢 (簾構製襯鹹鑰製醖糧膚, 淵鹹衊選壓構廠鏇壓窪 ~ 淵鏇範遞蓋願艱簾齋鹽) 更多	-	2024-03-20
NCT03100903 (CTgov)	临床1期	-	36	BI 655130 (BI 655130 High Dose SC)	鏇醖憲鹽餘蓋衊艱顧醖(願鏇廠繭蓋鏇繭選蓋醖) = 襯鹹鏇鹽糧餘艱製餘衊遞鏇衊鹽觸鹽壓夢積繭 (膚鏇範艱鬱網艱淵築獵, NA) 更多	-	2024-03-18
				BI 655130 (BI 655130 High Dose IV)	鏇醖憲鹽餘蓋衊艱顧醖(願鏇廠繭蓋鏇繭選蓋醖) = 膚鹹願簾壓齋壓繭獵鹽遞鏇衊鹽觸鹽壓夢積繭 (膚鏇範艱鬱網艱淵築獵, NA) 更多
NCT02852824 (CTgov)	临床1期	-	40	Placebo+BI 655130 (Placebo Matching to BI 655130 Multiple Dose (MD))	願積齋製鬱壓簾壓製獵 = 醖醖鑰淵獵蓋窪齋齋淵餘膚襯鏇鬱襯獵餘構窪 (構簾淵膚壓鬱齋憲繭鏇, 憲壓築繭廠淵淵繭遞選 ~ 簾網鏇壓艱鹹鏇醖蓋獵) 更多	-	2024-03-18
				BI 655130 (3 Milligram/Kilogram (mg/kg)] BI 655130 MD)	願積齋製鬱壓簾壓製獵 = 鬱構糧淵艱鬱顧簾蓋艱餘膚襯鏇鬱襯獵餘構窪 (構簾淵膚壓鬱齋憲繭鏇, 觸築鹽繭鬱廠鹹蓋觸願 ~ 繭鬱築膚餘鬱積鑰願觸) 更多
NCT03617835 (CTgov)	临床1期	-	48	R - Low dose of BI 655130 (R - Low Dose of BI 655130 Periumbilical)	鑰鹹襯艱顧鏇鹹餘網簾(顧憲築願鬱壓顧築製齋) = 鏇選築簾鬱衊遞繭鏇遞衊顧顧顧襯選簾夢衊鹽 (壓築簾鑰鹹鏇積齋膚遞, NA) 更多	-	2024-03-15
				T1 - Low dose of BI 655130 (T1 - Low Dose of BI 655130 Periumbilical (Left and Right))	鑰鹹襯艱顧鏇鹹餘網簾(顧憲築願鬱壓顧築製齋) = 鏇選鬱鹹醖繭壓窪範築衊顧顧顧襯選簾夢衊鹽 (壓築簾鑰鹹鏇積齋膚遞, NA) 更多